![Mayo Clinic home page [logo]](/images-global/mayologo.gif)
Discover how you can help support Mayo Clinic.
Below is a list of a few of the clinical trials at Mayo Clinic. More than 60 treatment protocols are currently open. Click here to see a list of clinical trials open in Arizona. If you have questions regarding opportunities to participate in Cancer Clinical Trials, please call (480) 301-9875.
Read about Pancreatic Cancer Research and Myeloma and Macroglobulinemia Research at Mayo Clinic.
US03 – Open-label Phase II Study of Exjade (deferasirox) for Treatment of Transfusional iron Overload in Low-Risk and INT-1, Transfusion-Dependent Myelodysplastic Patients using Ferritin Monitoring
Patients with myelodysplastic syndrome (MDS) who suffer from transfusional iron overload will have the opportunity to receive a new, exciting oral iron chelator free of charge that has been FDA approved for the use of reducing total body iron content. This is a 3 year study to continue to collect safety data.
E2903 Phase II trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia
This active regimen will be used to determine responses and toxicities for previously treated patients with CLL. Prior Rituximab therapy is allowed as is prior use of Fludarabine. Campath will be administered after PCR to obtain minimal residual disease status. Patients must be in need of treatment and must have reasonable organ function (creatinine <2, bilirubin < 2). Read more.
MC048C Phase II Trial of Avastin to Prevent or Delay Disease Progression in Patients with Relapsed/Refractory CLL
Increased angiogenesis is a common feature of malignancy and is present in marrows of CLL patients. This Ph II trial will examine the response and toxicity of the VEGF inhibitor, Avastin in CLL patients who have relapsed after Fludarabine or an alkylator. Patients are not eligible if they have received prior PCR. Patients should have a good performance status (ECOG < 3).
E2902 – A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission after Primary Induction Failure
ECOG protocol 2902 is a randomized study of Zarnestra (R115777) for patients with acute myeloid leukemia (AML) that is in remission following standard chemotherapy or autologous transplant. Eligible patients include any patient greater than 60 years of age in first CR, and patients of any age in second or subsequent remission, or in first remission following primary induction failure. Patients are randomized to receive R115777 400 mg bid or observation; treatment continues until unacceptable toxicity or relapse. Patients may have received consolidation therapy, including autologous stem cell transplant. All subtypes of AML are eligible except AML M3 (APL). Read more.
Intravenous (IV) Pentostatin, a Chemotherapy Drug, for the Treatment of Refractory (Resistent) Chronic Graft-Host Disease
This study is being done to find out what effects (good and bad) an investigational drug known as pentostatin has on a patient and chronic Graft-Versus-Host Disease (GVHD). Patients must have been diagnosed with Chronic Graft-Versus-Host Disease (GVHD) and failed treatment or progression of disease after receiving corticosteroids. Read more.
P02978-A Pivotal Randomized Study of Lonafarnib (SCH 66336) Versus Placebo in the Treatment of Subjects with Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who are Platelet Transfusion Dependent With or Without Anemia.
P02978 will enroll patients with any type of MDS, including CMML and RAEBt (according to the FAB schema), who are thrombocytopenic and requiring ongoing platelet transfusions. This is a randomized, placebo-controlled trial of Lonafarnib, a farnesyl transferase inhibitor developed by Schering-Plough. Patients must be > 12 weeks from any previous treatment of MDS, but otherwise may have received essentially any type of previous therapy, including allogeneic or autologous BMT. Lonafarnib (or placebo) is given orally, twice daily, for 12 weeks, when a response assessment is performed. Non-responding patients on the placebo arm can receive open label Lonafranib at this time. Read more.
E1900-A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification and Gemtuzumab-Ozogamicin Consolidation Therapy Prior to Autologous Stem Cell Transplantation
ECOG 1900 enrolls patients with AML (excluding M3 and patients with preceding known MDS) between the ages of 17 and 60. Patients are initially randomized to one of two induction regimens: standard dose daunorubicin (45 mg/M2/day x 3) versus high dose daunorubicin (90 mg/M2/day x 3), with Ara-C 100 mg/M2/day over 7 days. Patients who enter CR and are considered high risk (and who have a suitable family donor) are offered allogeneic BMT. All other patients are scheduled to receive autologous stem cell transplant following 2 cycles of high dose Ara-C consolidation, with half of the patients also receiving gemtuzumab ozogamicin 6 mg/M2 prior to autologous transplant. Stem cells are harvested following the second cycle of consolidation. Read more.
AML Daunorubicin/Dose Intensification and Gemtuzumab-ozogamicin Consolidation Rx Prior to Auto Stem Cell Transplant (E1900)
Leukemic cells from most patients with AML express CD33, a cell surface signaling molecule specific to the myeloid lineage. Gemtuzumab ozogamicin (Mylotarg) is FDA-approved to treat relapsed AML in patients above age 60. It is not yet known whether this agent will increase the cure rate in younger patients with AML, particularly if used earlier in the course of the disease. In ECOG 1900, younger AML patients (< age 61) with intermediate or adverse cytogenetic findings will be randomized to receive or not receive Mylotarg as part of their treatment prior to planned autologous stem cell transplant. Read more.
A Random, Open label Study of Oral CEP-701 Admin in Sequence with Standard Chemo to Patients with Relapsed AML Expressing FLT-3 mutation (C0701a/204)
Patients with relapsed AML whose leukemic cells harbor a FLT-3 internal tandem duplication (ITD) or mutation will be randomly assigned to receive standard salvage chemotherapy with or without a novel FLT-3 inhibitor (CEP-701). FLT-3 is a tyrosine kinase that can be constitutively activated in leukemia cells by one of several genetic mechanisms. Several small molecule inhibitors of FLT-3 have been developed, and CEP-701 is among the most promising. This trial seeks to determine if the addition of a CEP-701 to standard chemotherapy will increase the response rate and survival of patients with relapsed AML. Read more.
An Open Label Extended Use Study of Oral CEP-701 in Patients with Hematologic and Non-Hematologic Malignancies who have Completed a Clinical Study of CEP-701 (C0701a/501)
CEP-701 is a small molecule inhibitor of FLT-3, currently being tested in AML and other malignancies. Patients will be enrolled onto this study if they have previously received CEP-701 and have had a favorable response. Read more.
Phase 1 Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CHIR-258 in Subjects with Refractory or Relapsed Multiple Myeloma
This is a Phase 1 study that looks at the tolerability and safety of a small-molecule tyrosine kinase inhibitor of FGFR3/VEGFR in patients with relapsed and refractory myeloma. The drug is administered orally. FGFR3 is believed to be a critical survival factor for myeloma cells with t(4;14) translocation, and VEGFR is important for angiogenesis in all patients. Read more.
MC0482-Phase III Trial of Stem Cell Transplantation Compared to Parenteral Melphalan and Oral Dexamethasone in the Treatment of Primary Systemic Amyloidosis (AL)
Recent data suggest that Melphalan in smaller doses may be as active as high dose therapy for patients with primary Amyloidosis. This important trial will randomize patients to transplant or non-transplant arms and all patients will need to fulfill guidelines for entry prior to randomization.
Phase II Study of Melphalan Prednisone and CC5013 in Patients with MM NOT Candidates for Transplant (MC038A)
This trial is focused on improving the outcomes of patients undergoing treatment for myeloma and who are not candidates for stem cell transplant by adding the thalidomide analogue Revlimid™ to the regimen of melphalan and prednisone. Read more.
A Randomized Phase III study of CC-5013 plus Dexamethasone versus CC-5013 plus Low Dose Dexamethasone in MM with Thalidomide Plus Dexamthasone Salvage Therapy for Non- Responders (E4A03)
This is a high priority national trial that compares the use of Revlimid™ with dexamethasone administered at standard dose versus dexamethasone given at lower doses. The trial has a built in provision to allow treatment of patients who fail the initial combination by providing treatment with Thalidomide™ in combination with dexamethasone to non-responders. The trial is open only to patients who have received no prior therapies for myeloma (including corticosteroids) and who have symptomatic disease. The trial allows for stem cell collection after 4 months of treatment and continuation of the combination at the discretion of the treatment physician for patients deriving benefit from the combination. Read more.
A Phase III Randomized Trial of Thalidomide + Zoldronic Acid vs Zoldronic Acid Alone in Early MM (MC0289)
The goal of this trial is to assess whether the administration of thalidomide in combination with zoledronic acid can delay progression of MGUS and early stage MM to the active form of the disease. Read more.
RAD001 (Everolimus) for Relapsed or Refractory Lymphoma (MC048G)
RAD001 is a Rapamycin analog that induces apoptosis in lymphoma cells by inhibition of m-TOR, a key regulator of cell growth. The drug is given by mouth and is well tolerated. This trial will examine the response in patients with relapsed NHL and HL. All grades of NHL are eligible as well as patients with uncommon lymphomas such as Mycosis Fungoides and Anaplastic large cell lymphoma. Read more.
ROAD A Phase II Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone with Rituxan for Relapsed CD 20+ B-cell NHL (MC0485)
This is a salvage regimen like DHAP but with less potential toxicity. Eligibility requires aggressive histology, good organ function and no more than one prior chemotherapy regimen. Patients receive two cycles of therapy and would therefore be able to proceed to stem cell transplant if clinically indicated.
A Phase III Randomized, Double Blind Trial of FAVID and GM-CSF vs. Placebo and GM-CSF Following Rituximab in Follicular B-cell NHL (FAVID06)
The goal is to see if inoculation with idiotype-derived vaccine will improve the response rate or delay relapse in patients with follicular grades 1, 2 or 3 NHL. After biopsy to make the idiotype vaccine, patients are treated with Rituximab. Patients with stable or responding disease will then be randomized to receive their idiotype vaccine/GM-CSF or placebo/GM-CSF. Those that have progression on the placebo arm can crossover and receive active vaccine.
Monoclonal Antibody and Chemotherapy, R-CHOP, with Radioimmunotherapy, Zevalin, for Patients with Previously Untreated Stages 1 and 2 CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma
This study is being done to find out what effects (good and bad) a new treatment that combines standard CHOP chemotherapy [cyclophosphamide, hydroxydaunomycin (doxorubicin), oncovin (vincristine) and prednisone] with a monoclonal antibody (rituximab) followed by a single dose of a radioactive antibody (zevalin) has on a patient and diffuse large cell lymphoma. Rituximab is approved by the Food and Drug Administration (FDA) for other conditions, but not for diffuse large cell lymphoma. Read more.
N0489-A Phase II Study of ER-CHOP for Patients with Previously Untreated Stages III and IV Diffuse Large B-Cell Lymphoma
This study combines two monoclonal antibodies that target different B-cell antigens with standard CHOP. Preliminary data suggest minimal added toxicity. Patients need to have aggressive NHL CD20+ requiring therapy. Read more.
MC048G-Phase II Trial of RAD001 in Relpased/Refractory Lymphoma
This new oral agent is an M-Tor inhibitor that has cytotoxic activity against malignant lymphocytes. All subtypes of lymphoma are eligible and patients must have relapsed disease and not be eligible for stem cell transplantation. Read more.
Chemotherapy, Depsipeptide, in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
This phase II study is being done to determine: -how well the study drug, Depsipeptide, will work in the treatment of cutaneous T-cell lymphoma or peripheral T-cell lymphoma (types of cancer) Read more.
The ALLTO clinical trial compares different treatments in patients with early stage HER2-positive breast cancer. Read more about trial eligibility and find out about enrolling.
.
